News und Analysen
American Express Releases 2020-2021 Environmental, Social, and Governance Report with New Long-Term Goals
American Express (NYSE: AXP) today announced the release of its 2020-2021 Environmental, Social, and Governance (ESG) Report, which includes a new roadmap for the company’s ESG strategy focused on
American Express Releases 2020-2021 Environmental, Social, and Governance Report with New Long-Term Goals
American Express (NYSE: AXP) today announced the release of its 2020-2021 Environmental, Social, and Governance (ESG) Report, which includes a new roadmap for the company’s ESG strategy focused on
![Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Agehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in
![Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Agehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in
![Western Union Foundation Funds Education for Underserved Youth: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24835/375px-Western_Union_money_transfer.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc2tDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--0816ae8af05ddeb070c715750e96df42009b12d4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/375px-Western_Union_money_transfer.png?locale=de)
Western Union Foundation Funds Education for Underserved Youth
The Western Union Foundation today announced its latest USD 3.7 million Opportunity Beyond Borders investment in skills training, resources, and a new scholarship fund, helping prepare nearly
![Dassault Systèmes to Unveil Its Next “Design for Life” Installation at London’s Design Museum](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Dassault Systèmes to Unveil Its Next “Design for Life” Installation at London’s Design Museum
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) (Paris:DSY) today announced the next installation in its “Design for Life” program of collaborations with groundbreaking designers around
![Dassault Systèmes to Unveil Its Next “Design for Life” Installation at London’s Design Museum](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Dassault Systèmes to Unveil Its Next “Design for Life” Installation at London’s Design Museum
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) (Paris:DSY) today announced the next installation in its “Design for Life” program of collaborations with groundbreaking designers around
![Helmerich & Payne, Inc. Announces Upsize and Pricing of $550 Million Offering of 2.900% Senior Notes due 2031: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24508/Helmerich___Payne_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYzQ9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--6a7f9a6e08e010bc196afe244518a0e536956354/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Helmerich___Payne_logo.png?locale=de)
Helmerich & Payne, Inc. Announces Upsize and Pricing of $550 Million Offering of 2.900% Senior Notes due 2031
Helmerich & Payne, Inc. (NYSE:HP) (“H&P” or the “Company”) announced today that it has priced its previously announced private offering (the “Offering”) of $550 million aggregate principal amount
![Semtech to Participate in Upcoming Investor Event: https://mms.businesswire.com/media/20191106005365/en/1659/5/Semtech_stack_color_logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0FrRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3eab404c2b67e081278e6e848e75dc77dace506f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Semtech_stack_color_logo.jpg?locale=de)
Semtech to Participate in Upcoming Investor Event
Semtech Corporation (Nasdaq: SMTC), a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms, today announced that its Chief Executive Officer, Mohan
Gap Inc. Announces Closing of $1.5 Billion Senior Notes Offering
The Gap, Inc. (NYSE: GPS) (“Gap Inc.” or the “Company”) today announced it has closed its previously announced offering of $1.5 billion of senior notes (the “Notes”), consisting of $750 million
![Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Programhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program
Pfizer Inc. (NYSE: PFE) announced today that the first participants have been dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single dose
![Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Programhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program
Pfizer Inc. (NYSE: PFE) announced today that the first participants have been dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single dose
![PotlatchDeltic Scheduled to Release Third Quarter 2021 Earnings on October 25, 2021](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
PotlatchDeltic Scheduled to Release Third Quarter 2021 Earnings on October 25, 2021
PotlatchDeltic Corporation (Nasdaq: PCH) will release third quarter earnings on Monday, October 25, after the market closes. The company will hold a live conference call and webcast on Tuesday
![Chevron Mourns Passing of Former Texaco Chairman Alfred DeCrane](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Chevron Mourns Passing of Former Texaco Chairman Alfred DeCrane
Chevron Corporation today honored the life and career of former Texaco Chairman and CEO Alfred C. DeCrane, Jr., who died this past week at the age of 90.
This press release features multimedia
![Chevron Mourns Passing of Former Texaco Chairman Alfred DeCrane](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Chevron Mourns Passing of Former Texaco Chairman Alfred DeCrane
Chevron Corporation today honored the life and career of former Texaco Chairman and CEO Alfred C. DeCrane, Jr., who died this past week at the age of 90.
This press release features multimedia
![Keysight Technologies, National Central University Optical Sciences Center, Establish Third-generation Semiconductor R&D and Test Open Laboratory: https://mms.businesswire.com/media/20191105005173/en/754303/5/Keysight_Signature_Pref_Color.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1VqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bca68eb5e804e1802db2e2b6ef512db960c90ff6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Keysight_Signature_Pref_Color.jpg?locale=de)
Keysight Technologies, National Central University Optical Sciences Center, Establish Third-generation Semiconductor R&D and Test Open Laboratory
Keysight Technologies, Inc. (NYSE: KEYS), a leading technology company that delivers advanced design and validation solutions to help accelerate innovation to connect and secure the world, and
![Helmerich & Payne, Inc. Announces Private Offering of $500 Million of Senior Notes and Conditional Redemption of 4.65% Senior Notes due 2025: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24508/Helmerich___Payne_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBYzQ9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--6a7f9a6e08e010bc196afe244518a0e536956354/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Helmerich___Payne_logo.png?locale=de)
Helmerich & Payne, Inc. Announces Private Offering of $500 Million of Senior Notes and Conditional Redemption of 4.65% Senior Notes due 2025
Helmerich & Payne, Inc. (NYSE:HP) (“H&P” or the “Company”) announced today that it has commenced a private offering (the “Offering”) of $500 million aggregate principal amount of senior notes due
Gap Inc. Announces Early Tender Results of Cash Tender Offers and Consent Solicitations for Any and All of its Senior Secured Notes
The Gap, Inc. (NYSE: GPS) (“Gap Inc.” or the “Company”) today announced the early tender results of its (i) offers to purchase for cash (collectively, the “Tender Offers” and each a “Tender Offer”)
![PulteGroup’s Third Quarter 2021 Earnings Release and Webcast Conference Call Scheduled for October 26, 2021: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24721/Pulte_Group_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc3dDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--f0de83ff2b00bd43d3fb5a5ca0bc6f80f5ab530d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pulte_Group_logo.png?locale=de)
PulteGroup’s Third Quarter 2021 Earnings Release and Webcast Conference Call Scheduled for October 26, 2021
PulteGroup, Inc. (NYSE: PHM) today announced that it will release its third quarter 2021 financial results before the market opens on Tuesday, October 26, 2021. The Company will hold a conference
![Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
Pfizer Inc. (NYSE: PFE) today announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study to evaluate the investigational novel
![Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
Pfizer Inc. (NYSE: PFE) today announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study to evaluate the investigational novel
![Hackers help communities combat effects of dangerous floods at Europe's biggest hackathon](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Hackers help communities combat effects of dangerous floods at Europe's biggest hackathon
Global water technology company, Xylem, today congratulated a team of hackathon participants that has come up with a new way to respond to abrupt flood events. Team Res-Queue won HackZurich 2021’s
PMI Calls for Science-Based Discourse on Smoke-Free Alternatives
Misinformation threatens progress toward a smoke-free future, reveals a new international survey released today by Philip Morris International Inc. (PMI) (NYSE: PM). Well-funded groups continue to
![Transplant Genomics Launches OmniGraf™, the Only Combination Biomarker Panel That Provides the Earliest Indication of Rejection in Kidney Transplant Recipients: https://mms.businesswire.com/media/20200421005718/en/318625/5/EUROFINS_jpg.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzNhTUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--39aa1a81526ac2a70cd04ea71d1ab318c23b607c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/EUROFINS_.jpg?locale=de)
Transplant Genomics Launches OmniGraf™, the Only Combination Biomarker Panel That Provides the Earliest Indication of Rejection in Kidney Transplant Recipients
Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, is pleased to introduce OmniGraf™, which combines the TruGraf®